Glenmark PharmaceuticalsQ4 FY24

Glenmark Pharmaceuticals Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,615.8P/E: 36.4Market Cap: ₹73.8K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • RYALTRIS is in the launch phase with expected peak sales of $200-$300 million over the next 3-5 years.
  • Growth to be driven by expansions into major markets like Mexico, Brazil, and China starting FY'26.
  • Significant market share gains anticipated in Europe, emerging markets, and the US (where growth from partners like Hikma is expected).
  • European respiratory product launches and entry into new markets like the UK and South Africa also expected to fuel growth.
  • Emerging markets remain key growth drivers alongside established markets.
  • Plans to launch first generic Salmeterol + Fluticasone MDI in Brazil and generic Flovent in the US (FY'26), a $400+ million opportunity.
  • FY'26 flagged as a big year with substantial top line growth anticipated; additional capacity and CAPEX planned accordingly.
  • Overall, the company anticipates double-digit growth in sales driven by new product launches, market expansion, and increasing branded market contribution.

See what Glenmark Pharmaceuticals management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • No explicit mention of new fundraising through debt or equity was made in the Q4 FY'24 earnings call excerpts.
  • The company has a gross debt of Rs. 990.6 crores and a net cash position of Rs. 667.7 crores as of March 31, 2024.
  • CAPEX for FY'25 is budgeted at Rs. 700 crores, funded internally through cash flow, with no mention of external fundraising.
  • The management indicated plans for in-licensing of products rather than big M&A, suggesting a conservative capital approach.
  • No statements or guidance were provided indicating plans for raising new equity or debt financing in the near term.

See what Glenmark Pharmaceuticals management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Glenmark plans a consolidated capital investment (CAPEX) of Rs. 700 crores for FY'25.
  • This CAPEX excludes GLS-related investments, which were part of prior years.
  • The Rs.700 crores will be invested in:
  • - Adding new production lines to support business growth, including capacity for products like RYALTRIS.
  • - Potential in-licensing of additional products to expand the portfolio, rather than major M&A.
  • There is significant front-ended CAPEX planned this year to prepare for stronger performance expected in FY'26.
  • The Monroe facility's injectable line is expected to be commercialized this year while other lines are impaired and likely scrapped.
  • No big mergers or acquisitions are planned, but strategic in-licensing is a key focus to supplement organic growth.

Track Glenmark Pharmaceuticals — get its next earnings analysis in your feed

How does Glenmark Pharmaceuticals rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisGlenmark Pharmaceuticals
Rev 3Mar 3

How does Glenmark Pharmaceuticals rank in Pharmaceuticals & Biotechnology?

Compare Glenmark Pharmaceuticals against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →